Impact of SARS-CoV-2 on lung cancer patient under immunotherapy

1 Vivarelli S, Falzone L, Grillo CM, Scandurra G, Torino F, Libra M. Cancer management during COVID-19 pandemic: is immune checkpoint inhibitors-based immunotherapy harmful or beneficial? Cancers (Basel). 2020;12(8): 2237. doi:10.3390/cancers12082237. Search in Google Scholar

2 Tan J, Yang C. Prevention and control strategies for the diagnosis and treatment of cancer patients during the COVID-19 pandemic. British Journal of Cancer. 2020;123(1): 5–6. doi:10.1038/s41416-020-0854-2. Search in Google Scholar

3 Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. The Lancet Oncology. 2020;21(7): 914–922. doi:10.1016/S1470-2045(20)30314-4. Search in Google Scholar

4 Wang H, Zhang L. Risk of COVID-19 for patients with cancer. The Lancet Oncology. 2020;21(4): e181. doi:10.1016/S1470-2045(20)30149-2. Search in Google Scholar

5 Zhang H, Quek K, Chen R, Chen J, Chen B. Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer. Journal of Cancer. 2020;11(18): 5289–5292. doi:10.7150/jca.49462. Search in Google Scholar

6 Sha Z, Chang K, Mi J, Liang Z, Hu L, Long F, et al. The impact of the COVID-19 pandemic on lung cancer patients. Annals of Palliative Medicine. 2020;9(5): 3373–3378. doi:10.21037/apm-20-1662. Search in Google Scholar

7 Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discovery. 2020;10(6): 783–791. doi:10.1158/2159-8290.CD-20-0422. Search in Google Scholar

8 Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. The Journal of the American Medical Association. 2020;324(8): 782–793. doi:10.1001/jama.2020.12839. Search in Google Scholar

9 Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nature Reviews Immunology. 2015;15: 486–499. doi:10.1038/nri3862. Search in Google Scholar

10 Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Grzegrzolka J, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. International Journal of Molecular Sciences. 2019;20: 824. doi:10.3390/ijms20040824. Search in Google Scholar

11 Bian DJH, Sabri S, Abdulkarim BS. Interactions between COVID-19 and lung cancer: lessons learned during the pandemic. Cancers. 2022;14: 3598. doi:10.3390/cancers14153598. Search in Google Scholar

12 Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncology. 2022;8: 69–78. doi:10.1001/jamaoncol.2021.5148. Search in Google Scholar

13 Provencio M, Mazarico Gallego JM, Calles A, Antoñanzas M, Pangua C, Mielgo Rubio X, et al. Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer. 2021;157: 109–115. doi:10.1016/j.lungcan.2021.05.014. Search in Google Scholar

14 Sharafeldin N, Bates B, Song Q, Madhira V, Yan Y, Dong S, et al. Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C). Journal of Clinical Oncology. 2021;39: 2232–2246. doi:10.1200/JCO.21.01074. Search in Google Scholar

15 Ferrari BL, Ferreira CG, Menezes M, De Marchi P, Canedo J, Melo AC, et al. Determinants of COVID-19 mortality in patients with cancer from a community oncology practice in Brazil. JCO Global Oncology. 2021;7: 46–55. doi:10.1200/GO.20.00444. Search in Google Scholar

16 Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. Journal of Clinical Oncology. 2020;38: 3538–3546. doi:10.1200/JCO.20.01307. Search in Google Scholar

17 Liu H, Yang D, Chen X, Sun Z, Zou Y, Chen C, et al. The effect of anticancer treatment on cancer patients with COVID-19: a systematic review and meta-analysis. Cancer Medicine. 2021;10: 1043–1056. doi:10.1002/cam4.3692. Search in Google Scholar

18 Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. Journal of Clinical Oncology. 1996;14: 636–643. doi:10.1200/JCO.1996.14.2.636. Search in Google Scholar

19 Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2006;66: 1356–1365. doi:10.1016/j.ijrobp.2006.03.018. Search in Google Scholar

20 Abravan A, Eide HA, Helland Å, Malinen E. Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy. Clinical and Translational Radiation Oncology. 2020;22: 15–21. doi:10.1016/j.ctro.2020.02.005. Search in Google Scholar

21 Schneider JL, Rowe JH, Garcia-de-Alba C, Kim CF, Sharpe AH, Haigis MC. The aging lung: physiology, disease, and immunity. Cell. 2021;184: 1990–2019. doi:10.1016/j.cell.2021.03.005. Search in Google Scholar

22 Matanić D, Beg-Zec Z, Stojanović D, Matakorić N, Flego V, Milevoj-Ribić F. Cytokines in patients with lung cancer. Scandinavian Journal of Immunology. 2003;57: 173–178. doi:10.1046/j.1365-3083.2003.01205.x. Search in Google Scholar

23 Silva EM, Mariano VS, Pastrez PRA, Pinto MC, Castro AG, Syrjanen KJ, et al. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. Plos One. 2017;12: e0181125. doi:10.1371/journal.pone.0181125. Search in Google Scholar

24 Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clinical and Experimental Metastasis. 2011;28: 13–25. doi:10.1007/s10585-010-9354-8. Search in Google Scholar

25 Slotman BJ, Cremades V, Kirby AM, Ricardi U. European radiation oncology after one year of COVID-19 pandemic. Clinical and Translational Radiation Oncology. 2021;28: 141–143. doi:10.1016/j.ctro.2021.03.011. Search in Google Scholar

26 COVID-19 Pandemic has led to more advanced-stage cancer diagnoses, physician survey finds. American Society for Radiation Oncology. Available from: https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2021/COVID-19-pandemic-has-led-to-more-advanced-stage-c. [Accessed 18th July 2021]. Search in Google Scholar

27 Van Haren RM, Delman AM, Turner KM, Waits B, Hemingway M, Shah SA, et al. Impact of the COVID-19 pandemic on lung cancer screening program and subsequent lung cancer. Journal of the American College of Surgeons. 2021;232: 600–605. doi:10.1016/j.jamcollsurg.2020.12.002. Search in Google Scholar

28 Spigel DR, Reckamp KL, Rizvi NA, Poddubskaya E, Jack West H, Baas WEEEP, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). Journal Clinical Oncology. 2015;33: 8009. doi:10.1200/jco.2015.33.15_suppl.8009. Search in Google Scholar

29 Oncologypro – KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%, ESMO 21 Sep 2020. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/keynote-024-5-year-os-update-first-line-1l-pembrolizumab-pembro-vs-platinum-based-chemo-therapy-chemo-in-patients-pts-with-metastatic-nsclc Search in Google Scholar

30 Blin E, Adam SM. Les nouvelles pneumopathies interstitielles liées aux thérapies ciblées et immunothérapies new interstitial lung diseases due to targeted therapies and immunothera-pies. Revue des Maladies Respiratoires Actualités. 2016;8(2): 170–172. doi:10.1016/S1877-1203(16)30084-2. Search in Google Scholar

31 Le magazine des professionnels en santé respiratoire, effets secondaires de l’immunothérapie pour traiter le cancer pulmonaire, 2020, October. Available from: file:///C:/Users/Pc/Downloads/rqesr_octobre2020_low(1).pdf Search in Google Scholar